Abstract: Object of the invention is a synthetic peptide, in particular a synthetic peptide to be used as medicament, in particular to be used in the treatment of neurodegenerative diseases and Amyotrophic Lateral Sclerosis (ALS), and compositions comprising such synthetic peptide. Furthermore, the invention concerns processes for the preparation of said synthetic peptide.

Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.

Abstract: The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease.

Abstract: Aspects of the present invention relate to peptides having antimicrobial activity. In certain aspects, the invention relates to peptides having potent antimicrobial activity, broad-spectrum antimicrobial activity, and/or the ability to kill otherwise antibiotic-resistant microbes, or microbes protected by biofilms.

Abstract: This disclosure relates to a method of preventing or treating a recurrence of acute otitis media in a subject at risk comprising administering a therapeutically effective amount of a composition, at least once to the subject.

Abstract: The present invention is a DNA expression vector comprising: a toxP; a mutant toxO that blocks Fe-mediated regulation of gene expression; and a DNA sequence encoding a protein, wherein the toxP and the mutant toxO regulate expression of the DNA segment encoding the protein. It is preferred that DNA expression vectors of the present invention include DNA sequences encoding a signal peptide so that a protein expressed is attached to the signal peptide prior to processing. Novel proteins are produced off of the DNA expression vector of the present invention.

Abstract: The present invention provides a modified oleosin protein, a polynucleotide sequence encoding the modified protein, and a method for regulating subcellular lipid distribution by recombinantly expressing the modified oleosin protein. This invention also provides a method for generating cells and organisms comprising the modified oleosin protein and exhibiting an altered subcellular lipid distribution pattern, as well as cells and organisms generated by such a method.

Abstract: The invention relates to recombinant microorganisms and methods for producing gibberellin compounds and gibberellin precursors.

Abstract: The present invention relates to a nanosphere comprising an equal number of a human SEC14-like protein and a cognate ligand of said SEC14-like protein as well as to methods of producing the same and uses of said nanospheres.

Abstract: The present disclosure provides opsins, including variant opsins with increased activity and/or increased trafficking to the plasma membrane. The opsins are useful in therapeutic and screening applications, which are also provided.

Abstract: The invention discloses a recombinant complement factor H (CFH)-immunoglobulin (Ig) fusion protein CFH-Ig with complement regulating activity, more specifically, complement regulating activity in the alternative complement pathway, and at the same time with the effect of targeting to tissues or cells where there is overactivation of complement. The invention further relates to a method for preparation of the fusion protein. The invention also relates to a pharmaceutical composition that contains the aforementioned fusion protein for treating autoimmune diseases or other diseases mediated by, or caused by disregulation or deficiency in the alternative complement pathway, as well as preventing or treating thrombosis caused by excessive complement activation in humans or other mammals.

Abstract: The present invention provides: a peptide which shows a hair growth-promoting activity and/or a melanin generation-promoting activity; a composition for preventing and/or alleviating hair loss, comprising the peptide as an effective ingredient; a composition for promoting hair growth, comprising the peptide as an effective ingredient; a use of the peptide for preventing and/or alleviating hair loss; a use of the peptide for promoting hair growth; a pharmaceutical composition for preventing and/or treating hypomelanosis, comprising the peptide as an effective ingredient; a cosmetic composition for preventing and/or treating hypomelanosis, comprising the peptide as an effective ingredient; and a use of the peptide for preventing and/or treating hypomelanosis.

Abstract: A further characterization and purification of recombinant human biglycan is provided. A biglycan polypeptide that lacks glycosaminoglycan side chains and is modified on cysteine 150 is provided. This biglycan polypeptide is used in compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan.

Abstract: The present disclosure provides recombinant polypeptides, homodimeric and heterodimeric proteins comprising the recombinant polypeptides, nucleic acid molecules encoding the recombinant polypeptides, and vectors and host cells comprising the nucleic acid molecules. The present disclosure also provides compositions comprising the recombinant polypeptides and methods of making and using the recombinant polypeptides.

Abstract: The present invention relates in general to a nucleic acid encoding human granulocyte-colony stimulating factor (G-CSF), wherein the first leucine residue occurring on the N-terminal end of the encoded G-CSF is encoded by a codon other than the CTG/CUG codon, and wherein the nucleic acid does neither comprise the nucleic acid sequence according to SEQ ID NO: 1, nor according to SEQ ID NO: 2, nor according to SEQ ID NO: 3, nor according to SEQ ID NO: 4. The present invention also relates to a nucleic acid 100% complementary to the aforementioned nucleic acid, as well as to vectors and host cells comprising the aforementioned nucleic acids. Finally, the present invention relates to methods for producing human G-CSF using these nucleic acids, vectors and/or host cells and resulting G-CSF compositions.

Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.

Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

Abstract: The present invention relates to the field of genetic engineering, in particular, to a transposon-based transfection kit suitable for transfection of primary cells, such as T cells, comprising mRNA encoding a transposase, or reagents for generating mRNA encoding said transposase, as well as minicircle DNA comprising the transposon. The invention also relates to a nucleic acid, preferably, a DNA minicircle, comprising a transposon, wherein the transposon encodes a protein and at least one miRNA, wherein the sequences encoding the miRNA are located in an intron and expression of the protein and the miRNA is regulated by the same promoter. The invention also provides a population of cells obtainable with the method of the invention. Methods of transfection are also provided, as well as medical use, e.g. in immunotherapy, in particular, in adoptive T cell therapy or T cell receptor (TCR) or chimeric antigen receptor (CAR) gene therapy.

Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel nuclear receptors comprising a substitution mutation and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene within a host cell using this inducible gene expression system.

Abstract: The present invention provides a therapy for treating loss of GABA-mediated pre-synaptic inhibition after spinal injury. The therapeutic regimen includes spinal segment-specific upregulation of GAD65 (glutamate decarboxylase) and VGAT (vesicular GABA transporter) to modulate chronic spasticity in patients after spinal traumatic or ischemic injury.

Abstract: In some aspects the present invention provides methods for the treatment of B-cell lymphomas. Some such methods involve administration of HVEM ectodomain polypeptides, anti-HVEM antibodies, or anti-BTLA antibodies to subjects in need thereof. Some such methods involve use of CAR T cells, such as CD19-specific CAR T cells. The present invention also provides compositions useful in such methods. These and other embodiments of the present invention and described further herein.

Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.

Abstract: Disclosed herein are methods of preventing incidence of a migrainous or non-migrainous post-ictal headache, and/or at least one secondary symptom associated with a migrainous post-ictal headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided.

Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.

Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.

Abstract: A composition and a method for the treatment of a neurodegenerative disorder is provided. The composition includes an inhibitor of RANTES and/or an inhibitor of eotaxin. The method includes administering a composition comprising an inhibitor of RANTES and/or an inhibitor of eotaxin to the subject in need thereof to treat the neurodegenerative disorder.

Abstract: The present invention provides, among other things, methods and compositions for delivering an antibody in vivo by administering to a subject in need thereof one or more mRNAs encoding a heavy chain and a light chain of an antibody, and wherein the antibody is expressed systemically in the subject. In some embodiments, the one or more mRNAs comprise a first mRNA encoding the heavy chain and a second mRNA encoding the light chain of the antibody.

Abstract: The present invention provides certain improved formulations of proteins. Specifically, the present invention provides use of certain excipients that are useful for stabilization of antibody preparations. Additionally, the novel formulation of the present invention prevents the formation of aggregates or fragments or modification of protein in solution.

Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (IL-21) and uses thereof, e.g., in therapy.

Abstract: Antigen binding proteins that bind to human IL-23 protein arc provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes arc also provided.

Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.

Abstract: The present invention relates to the biomedicine field, in particular to an anti-human PD-1 humanized monoclonal antibody and its applications. The invention obtains an anti-human PD-1 humanized monoclonal antibody with good specificity, high affinity and stability by screening, and the antibody can specifically bind to human PD-1 instead of binding to other members of CD28 family, block the binding of PD-L1 and PD-1 with CD80 and partially restore functions of T-cells, so it can significantly inhibit the growth of tumor.

Abstract: Disclosed herein are methods and compositions for targeting a complex comprising a non-classical HLA-I and a neoantigen in cancer. Further disclosed herein are antibodies that selectively bind to a complex comprising a non-classical HLA-I and a neoantigen, as well as methods of use thereof.

Abstract: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.

Abstract: Provided herein are monoclonal antibodies that recognize, bind to, and block interactions of other molecules with integrin ?8?1. Also provided herein are methods of using said antibodies to treat gastrointestinal motility disorders.

Abstract: Certain embodiments are directed to methods of treating LLT1 expressing cancer by administering to a subject having an LLT1 expressing cancer an LLT1 inhibitor.

Abstract: The technology provided herein generally relates to novel specific photoimmuno-theranostics for the use in detection and elimination of skin cancer cells. The technology also relates to novel methods which generate homogeneous and specific photoimmuno-theranostics reagents in a simple, controlled and efficient way. This method combines molecular optical imaging, photodynamic therapy and immunotherapy using SNAP-tag technology.

Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.

Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.

Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.

Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.

Abstract: The present application discloses a previously unknown function of CD24 expressed on a subset of dendritic cells. The invention encompasses regulating CD24 on these cells to regulate erythropoiesis, induce EPO production and levels, increase RBC levels, and to treat, for example, stress-mediated erythropoiesis. The compositions and methods of the invention are useful, for example, in treating anemia.

Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.